These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

111 related articles for article (PubMed ID: 38511642)

  • 1. PHF19 before and post induction treatment possess favorable potency of reflecting treatment response to protease inhibitors, event-free survival, and overall survival in multiple myeloma patients.
    An H; Chen S; Zhang X; Ke S; Ke J; Lu Y
    Hematology; 2024 Dec; 29(1):2331389. PubMed ID: 38511642
    [TBL] [Abstract][Full Text] [Related]  

  • 2. PHD finger protein 19 expression in multiple myeloma: Association with clinical features, induction therapy outcome, disease progression, and survival.
    Li Y; Gong J; Zhang L
    J Clin Lab Anal; 2021 Sep; 35(9):e23910. PubMed ID: 34390275
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Circular RNA_0003489 reflects unfavorable treatment response and shortened survival in newly diagnosed multiple myeloma patients who receive bortezomib-based induction therapy.
    Song S; Xie J; Xu B; Ran Q
    Hematology; 2024 Dec; 29(1):2399419. PubMed ID: 39268977
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cell division cycle 37 change after bortezomib-based induction therapy helps to predict clinical response and prognosis in multiple myeloma patients.
    Lin W; Chen X; Zheng H; Cai Z
    Hematology; 2023 Dec; 28(1):2231741. PubMed ID: 37409850
    [TBL] [Abstract][Full Text] [Related]  

  • 5. LDH is an adverse prognostic factor independent of ISS in transplant-eligible myeloma patients receiving bortezomib-based induction regimens.
    Chim CS; Sim J; Tam S; Tse E; Lie AK; Kwong YL
    Eur J Haematol; 2015 Apr; 94(4):330-5. PubMed ID: 25135740
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Polycomb-like Protein 3 Induces Proliferation and Drug Resistance in Multiple Myeloma and Is Regulated by miRNA-15a.
    Yu T; Du C; Ma X; Sui W; Yu Z; Liu L; Zhao L; Li Z; Xu J; Wei X; Zhou W; Deng S; Zou D; An G; Tai YT; Tricot G; Anderson KC; Qiu L; Zhan F; Hao M
    Mol Cancer Res; 2020 Jul; 18(7):1063-1073. PubMed ID: 32312841
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Retrospective analysis of the efficacy and influencing factors of autologous hematopoietic stem cell transplantation for multiple myeloma.
    Zhang BL; Zhou J; Lin QD; Liu YZ; Zhang YL; Gui RR; Song YP; Fang BJ
    Artif Organs; 2019 Oct; 43(10):1028-1034. PubMed ID: 30972806
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Revised International Staging System Is Predictive and Prognostic for Early Relapse (<24 months) after Autologous Transplantation for Newly Diagnosed Multiple Myeloma.
    Gopalakrishnan S; D'Souza A; Scott E; Fraser R; Davila O; Shah N; Gale RP; Kamble R; Diaz MA; Lazarus HM; Savani BN; Hildebrandt GC; Solh M; Freytes CO; Lee C; Kyle RA; Usmani SZ; Ganguly S; Assal A; Berdeja J; Kanate AS; Dhakal B; Meehan K; Kindwall-Keller T; Saad A; Locke F; Seo S; Nishihori T; Gergis U; Gasparetto C; Mark T; Nieto Y; Kumar S; Hari P
    Biol Blood Marrow Transplant; 2019 Apr; 25(4):683-688. PubMed ID: 30579965
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Prognostic value of the Second Revision of the International Staging System in patients with newly diagnosed transplant-eligible multiple myeloma].
    Zhou HX; Jian Y; Du J; Liu JR; Zhang ZY; Geng CY; Yang GZ; Wang GR; Fu WJ; Li J; Chen WM; Gao W
    Zhonghua Nei Ke Za Zhi; 2024 Jan; 63(1):81-88. PubMed ID: 38186122
    [No Abstract]   [Full Text] [Related]  

  • 10. The quantification of circular RNA 0007841 during induction therapy helps estimate the response and survival benefits to bortezomib-based regimen in multiple myeloma.
    Guo Y; Feng X; Wang Z; Zhang R; Zheng K; Xu J; Hu P; Zhang R
    Ir J Med Sci; 2024 Feb; 193(1):17-25. PubMed ID: 37336827
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Impact of Induction Therapy with VRD versus VCD on Outcomes in Patients with Multiple Myeloma in Partial Response or Better Undergoing Upfront Autologous Stem Cell Transplantation.
    Sidana S; Kumar S; Fraser R; Estrada-Merly N; Giralt S; Agrawal V; Anderson LD; Aljurf M; Banerjee R; Bashey A; Battiwalla M; Beitinjaneh A; Chakraborty R; Chhabra S; Dhakal B; Dholaria B; Hashmi S; Janakiram M; Lee C; Lekakis L; Murthy HS; Parrondo R; Wangjam T; Usmani S; Shah N; Qazilbash M; D'Souza A
    Transplant Cell Ther; 2022 Feb; 28(2):83.e1-83.e9. PubMed ID: 34781066
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Treatment outcome and prognostic factor analysis in transplant-eligible Chinese myeloma patients receiving bortezomib-based induction regimens including the staged approach, PAD or VTD.
    Chim CS; Lie AK; Chan EY; Liu HS; Lau CW; Yip SF; Sim J; Wan TS; Ma ES; Liang R; Tse E; Kwong YL;
    J Hematol Oncol; 2012 Jun; 5():28. PubMed ID: 22682027
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Insights into high-risk multiple myeloma from an analysis of the role of PHF19 in cancer.
    Ghamlouch H; Boyle EM; Blaney P; Wang Y; Choi J; Williams L; Bauer M; Auclair D; Bruno B; Walker BA; Davies FE; Morgan GJ
    J Exp Clin Cancer Res; 2021 Dec; 40(1):380. PubMed ID: 34857028
    [TBL] [Abstract][Full Text] [Related]  

  • 14. PHF19 inhibition as a therapeutic target in multiple myeloma.
    Schinke CD; Bird JT; Qu P; Yaccoby S; Lyzogubov VV; Shelton R; Ling W; Boyle EM; Deshpande S; Byrum SD; Washam C; Mackintosh S; Stephens O; Thanendrarajan S; Zangari M; Shaughnessy J; Zhan F; Barlogie B; van Rhee F; Walker BA
    Curr Res Transl Med; 2021 Jul; 69(3):103290. PubMed ID: 33894670
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Correlation of A-Kinase Interacting Protein 1 With Clinical Features, Treatment Response, and Survival Profiles in Patients With Multiple Myeloma.
    Wang W; Xie Y; Han X; Liu Y; Li P
    Technol Cancer Res Treat; 2020; 19():1533033820935856. PubMed ID: 32799782
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Total therapy with tandem transplants for newly diagnosed multiple myeloma.
    Barlogie B; Jagannath S; Desikan KR; Mattox S; Vesole D; Siegel D; Tricot G; Munshi N; Fassas A; Singhal S; Mehta J; Anaissie E; Dhodapkar D; Naucke S; Cromer J; Sawyer J; Epstein J; Spoon D; Ayers D; Cheson B; Crowley J
    Blood; 1999 Jan; 93(1):55-65. PubMed ID: 9864146
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evaluation of Revised International Staging System (R-ISS) for transplant-eligible multiple myeloma patients.
    González-Calle V; Slack A; Keane N; Luft S; Pearce KE; Ketterling RP; Jain T; Chirackal S; Reeder C; Mikhael J; Noel P; Mayo A; Adams RH; Ahmann G; Braggio E; Stewart AK; Bergsagel PL; Van Wier SA; Fonseca R
    Ann Hematol; 2018 Aug; 97(8):1453-1462. PubMed ID: 29623394
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Circular RNA_0000190 and its target microRNA-767-5p are dysregulated, and they are related to risk stratification as well as prognosis in multiple myeloma patients.
    Xiang Y; Xu X; Yang B; Wu Z; Jiang R; Xie Y
    Ir J Med Sci; 2022 Apr; 191(2):671-679. PubMed ID: 33864191
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Predictive value of post-transplant bone marrow plasma cell percent in multiple myeloma patients undergone autologous transplantation.
    Hwang IH; Chung JS; Shin HJ; Choi YJ; Song MK; Seol YM; Cho GJ; Choi BG; Choi MK; Choi BK; Ahn KH; Shin KH; Lee HS; Nam HS; Hwang JM
    Korean J Intern Med; 2011 Mar; 26(1):76-81. PubMed ID: 21437166
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Long-term follow-up of multiple myeloma after autologous hematopoietic stem cell transplantation: a single center results].
    Sui WW; Zou DH; An G; Yi SH; Deng SH; Huang WY; Wang TY; Li J; Liu H; Fu MW; Lyu R; Liu W; Xu Y; Li ZJ; Zhao YZ; Qiu LG
    Zhonghua Xue Ye Xue Za Zhi; 2017 Jun; 38(6):499-504. PubMed ID: 28655093
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.